Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New Online Tool Helps Patient Advocates Navigate Medicines Development and Evaluation Process


News provided by

Eli Lilly and Company

24 Mar, 2014, 09:07 GMT

Share this article

Share toX

Share this article

Share toX

INDIANAPOLIS, March 24, 2014 /PRNewswire/ --



A new online, interactive training programme designed to help patient advocates better influence decisions related to access to new medicines was launched today in advance of the 6th  Global  Patient  Congress at Ascot, United Kingdom.

Developed by Eli Lilly and Company in collaboration with internationally renowned experts in the fields of patient involvement and health technology assessment (HTA), the eMEET (Medicine Evaluation Educational Training) online resource is a unique tool designed to help patient advocates navigate the complex world of medicines development, evaluation and assessment. eMEET is endorsed by Health Technology Assessment International (HTAi), the global scientific and professional society for those who produce, use, or encounter HTA.[1]

"The growing role of patient engagement in the medicines evaluation process is one of the key drivers to improving access - and patient advocates have much to contribute," commented clinical expert Professor Ken Paterson, Former Chair, Scottish Medicines Consortium. "By helping ensure patients have a voice, it's a win for the healthcare system, a win for the HTA process and most importantly, a win for patients."

Patients have unique knowledge about what it's like to live with an illness, the possible limitations of existing treatments and the potential of new therapies. However, ensuring that patients' experiences are considered can be challenging in an environment where decisions are scientifically based.

"It's absolutely crucial that patient advocates understand the medicine development and HTA processes. Advocates can then make a more robust contribution to the medicines evaluation discussion and be accepted as an equal and knowledgeable stakeholder in healthcare decisions," said Kathy Oliver, Co-director for the International Brain Tumour Alliance (IBTA). "eMEET is a great resource. It's easily accessible online, you can learn at your own pace, and it's an enjoyable and valuable educational tool."

eMEET uses a variety of tools, such as video presentations, animations and exercises to show how patients' experiences can be integrated into these complex processes. The programme helps patient advocates ensure, in the most productive and meaningful way, that their input to the medicines evaluation process successfully highlights patient issues, informs decision-making and aligns with the scientific evidence.

"Evidence from patients can help us understand the challenges associated with current therapies and what they would want from new treatments," said Dr. Karen Facey, HTAi Interest Group for Patient/Citizen involvement in HTA. "This can help us put the scientific evidence into context and understand the true value of a treatment."

The eMEET training programme is presented in modules focused on:

  1. Introduction  and  scene-setting  - the  true  value  of  the  patient  voice
  2. The  journey  of  a  medicine - the  complex  process  of  medicines  discovery,  development  and  evaluation
  3. An  introduction  to  HTA
  4. HTA  in  practice - an  illustration  of  the  complexities  of  health  technology  assessment
  5. Patient  advocacy  group  participation  in  HTA  - how  to  engage  effectively  to  ensure  that  HTA  panels  understand  patients'  needs  and  preferences

eMEET is the online component of the broader MEET programme. Translated into multiple languages, MEET was developed as an interactive one-day training workshop designed to help patient advocacy group leaders understand and engage in the journey of a medicine, including: clinical trials, regulatory evaluation and HTA. eMEET does not focus on any specific disease state. MEET and eMEET are part of the advocacy component of PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative. For more information, please visit http://www.meetforpatients.com.

To view the multi-media press release, including the MEET video testimonials, eMEET teaser video and eMEET brochure please click the link below.

www.epresspack.net/mmr/news/5296

About  HTA

According to Health Technology Assessment International's "HTAi Patient and Consumer Glossary," health technology assessment is the "systematic evaluation of the clinical effectiveness and/or cost-effectiveness and/or the social and ethical impact of a health technology" (such as a medicine) "on the lives of patients and the healthcare system." Its aim is to educate healthcare policymakers. HTA organisations, such as NICE (National Institute for Health and Care Excellence) in the United Kingdom, recommend whether a specific health technology should be used, and if so, in which setting and for which patients. According to the glossary, "assessments vary, but most look at the health benefits and risks of using the technology. They also look at costs and any wider impacts that the technology might have on a population or on society."[2]

About  PACE 

Created by Lilly Oncology as a global collaboration spanning diverse sectors, PACE (Patient Access to Cancer care Excellence) exists to encourage public policies and healthcare decisions that speed the development of new medicines, assure cancer treatments respond to the needs and qualities of individual patients, and improve patient access to the most effective cancer medicines. PACE is engaging key oncology stakeholders: patients, advocacy, payers, policymakers, providers, the public, researchers and politicians. To learn more about PACE and the PACE  Cancer  Perception  Index, please visit http://www.pacenetwork.com.

About  Lilly  Oncology

For more than fifty years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly's commitment to people with cancer, please visit http://www.LillyOncology.com.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com and http://newsroom.lilly.com/social-channels.

References:

1. Health Technology Assessment International. What is HTAi? Available at http://www.htai.org/index.php?id=428. Accessed 21 March 2014.

2. Health Technology Assessment International. HTAi Patient and Consumer Glossary: A beginner’s guide to words used in health technology assessment. October 2009. Available at http://www.ihe.ca/documents/HTAiPatientAndConsumerGlossaryOctober2009_01.pdf. Accessed 21 March 2014.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.